Chardan Capital reiterated coverage on Exicure with a new price target

11/23/21 8:42:55 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Chardan Capital reiterated coverage of Exicure with a rating of Buy and set a new price target of $2.25 from $7.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$XCUR

Date	Price Target	Rating	Analyst
12/13/2021	$2.25 → $0.40	Buy → Neutral	Chardan Capital Markets
11/23/2021	$7.00 → $2.25	Buy	Chardan Capital